• Astellas Pharma reached a voluntary agreement with the U.S. government focused on medicine affordability, access, supply-chain resilience.
• Deal includes lower Medicaid prices, pricing framework for future drugs aligned with other developed nations.
• Supply-chain measures include a 25 kg tacrolimus API donation to the U.S. Strategic Active Pharmaceutical Ingredients Reserve.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astellas Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG37289) on August 31, 2026, and is solely responsible for the information contained therein.